Scholar Rock Holding's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Scholar Rock Holding (SRRK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Scholar Rock Holding vs Its Competitors
- TTM: Trailing 12-month revenue of 47M vs 99,497M combined for its competitors (0.0% combined share).
- Scale: Scholar Rock Holding ranks #20 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.7% of industry market cap.
- Peer differentiation: Revenue per employee of $0.16M compares with $1.75M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Scholar Rock Holding vs. its Competitors, Q2 2026
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Scholar Rock Holding reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Scholar Rock Holding and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Scholar Rock Holding Corp | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Scholar Rock Holding's competitor groups requires a Commercial License.
Scholar Rock Holding's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Scholar Rock Holding Corp | - | - | - | Yes |
| Competitors combined (27) | ||||
| High-Confidence Competitors (9) | ||||
| Similar-Size Competitors (9) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SRRK Stock Performance relative to its Competitors
SRRK Stock Performance relative to High-Confidence Competitors
SRRK Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 2 | Relay Therapeutics Inc | 282.9% | Outperformed |
| 3 | Agenus Inc | 282.9% | Outperformed |
| 4 | Biogen Inc | 282.9% | Outperformed |
| 5 | Cullinan Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Scholar Rock Holding's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Scholar Rock Holding Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Scholar Rock Holding Corp |
6,269.41 | 47.30 |
 Amgen Inc |
254,015.58 | 38,903.00 |
 Gilead Sciences Inc |
213,758.37 | 30,988.00 |
 Regeneron Pharmaceuticals Inc |
96,735.94 | 16,896.20 |
 Biogen Inc |
37,430.35 | 10,297.30 |
 Halozyme Therapeutics Inc |
12,626.48 | 1,802.45 |
| SUBTOTAL | 648,081.44 | 101,379.88 |
Sign in to see all competitors of Scholar Rock Holding Corp.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Scholar Rock Holding Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Scholar Rock Holding's Competitors Named by the Company
Competitive relationships identified from Scholar Rock Holding reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Keros Therapeutics Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Roche | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Merck | Company report | 85% |
| Cytokinetics, Inc. | Company report | 85% |
| Tilos Therapeutics | Company report | 85% |
| Novartis | Company report | 85% |
| Biogen | Company report | 85% |
| GSK | Company report | 85% |
Company report basis, confidence, active dates and source counts for Scholar Rock Holding's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Scholar Rock Holding's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Scholar Rock Holding's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Scholar Rock Holding Corp | 6,269 | 163,671 | -1,413,810 |
| Amgen Inc | 254,016 | 2,992,538 | 722,385 |
| Gilead Sciences Inc | 213,758 | 1,822,824 | -227,235 |
| Regeneron Pharmaceuticals Inc | 96,736 | 1,096,444 | 312,615 |
| Biogen Inc | 37,430 | 1,372,973 | 46,333 |
| Halozyme Therapeutics Inc | 12,626 | 4,261,106 | 1,147,565 |
| PEERS TOTAL | 641,812 | 1,754,464 | 158,321 |
Sign in to see all peers for Scholar Rock Holding Corp.
Scholar Rock Holding's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 76.66 % |
| Iovance Biotherapeutics inc | US 98.66 % |
| Agenus Inc | US 100.00 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Scholar Rock Holding's Position in Industry Market Structure
Market-capitalization share and concentration across all 157 companies in Scholar Rock Holding's industry classification, broader than the peer set above. Market cap in millions of $.Scholar Rock Holding ranks #20 of 157 companies by market capitalization in its industry, holding 0.69 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,390, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 251,872 | 26.22 % |
| 2 | Gilead Sciences Inc | 210,365 | 21.90 % |
| 3 | Moderna Inc | 105,074 | 10.94 % |
| 4 | Argenx Se | 63,976 | 6.66 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Kymera Therapeutics Inc | 1,234 | 5.2% |
| 20 | Scholar Rock Holding Corp | 6,605 | 0.69 % |
Market cap and industry share for the rest of Scholar Rock Holding's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-10.
Scholar Rock Holding's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 15 | Krystal Biotech Inc | 9,277 | 52.88 % |
| 16 | Twist Bioscience Corporation | 8,289 | 338.83 % |
| 18 | Immunitybio inc | 7,392 | 230.52 % |
| 19 | Kodiak Sciences Inc | 6,628 | 500.26 % |
| 20 | Scholar Rock Holding Corp | 6,605 | 74.68 % |
| 21 | Cg Oncology Inc | 1,234 | 12.3% |
| 22 | Adaptive Biotechnologies Corporation | 1,234 | 12.3% |
| 23 | Crispr Therapeutics Ag | 1,234 | 12.3% |
| 24 | Relay Therapeutics Inc | 1,234 | 12.3% |
| 25 | Denali Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Scholar Rock Holding's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-10. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Scholar Rock Holding's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.6x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | 24.7x | 5.3x | +19.5x |
| Return on Equity | -160.19 % | industry aggregate | -158.65 % |
| Return on Invested Capital | -67.65 % | -10.86 % (avg) | -56.79 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Scholar Rock Holding's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | 22.16 % | - | - | - | - |
| Operating Margin | - | -564.03 % | -690.48 % | - | - | - | - |
| Return on Invested Capital | - | -26.40 % | -28.15 % | -22.88 % | -36.53 % | -57.43 % | -70.76 % |
| P/E | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Scholar Rock Holding's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Scholar Rock Holding falls in the Dog quadrant: relative market share of 0.03x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Scholar Rock Holding's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,390 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Scholar Rock Holding's dedicated Suppliers and Customers pages, not here.
Scholar Rock Holding's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Scholar Rock Holding falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Scholar Rock Holding's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 158.7 points below the industry aggregate.
- Low relative market share vs the industry leader (0.03x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (61.50 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Scholar Rock Holding's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Scholar Rock Holding Corp | 5.93 | 7.21 | 0.58 |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| Biogen Inc | 0.08 | 2.33 | 0.38 |
| Halozyme Therapeutics Inc | 1.20 | 3.39 | 27.15 |
Sign in to see all peers for Scholar Rock Holding Corp.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Scholar Rock Holding's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Scholar Rock Holding Corp | Q2 2026 | - | - |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| Biogen Inc | Q3 2026 | +10.6 % | - |
| Halozyme Therapeutics Inc | Q3 2026 | +39.2 % | +41.0 % |
| PEERS TOTAL | +13.3 % | +0.7 % |
Sign in to see all peers for Scholar Rock Holding Corp.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Scholar Rock Holding's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Scholar Rock Holding Corp | Q2 2026 | - | -99.5 % |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| Biogen Inc | Q3 2026 | +11.0 % | -21.6 % |
| Halozyme Therapeutics Inc | Q3 2026 | +49.3 % | +0.7 % |
Sign in to see all peers for Scholar Rock Holding Corp.
Scholar Rock Holding's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Scholar Rock Holding Corp | - | - | - |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Gilead Sciences Inc | - | - | - |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| Biogen Inc | 1.13% | 1.26% | 1.86% |
| Halozyme Therapeutics Inc | 17.26% | 19.64% | 544.26% |
Sign in to see all peers for Scholar Rock Holding Corp.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Scholar Rock Holding's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Scholar Rock Holding Corp | - | 132.54 |
| Amgen Inc | 26.97 | 6.53 |
| Gilead Sciences Inc | - | 6.90 |
| Regeneron Pharmaceuticals Inc | 20.26 | 5.73 |
| Biogen Inc | 108.14 | 3.63 |
| Halozyme Therapeutics Inc | 25.81 | 7.01 |
| PEERS AVERAGE | 74.19 | 6.39 |
Sign in to see all peers for Scholar Rock Holding Corp.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.